EXOLITUS | Exosome Technologies

Exosome-based treatment for COVID-19-induced acute respiratory dysfunction


Funding source: EU Regional Funds
Funding Institution: Agency for Science, Innovation and Technology of Lithuania
Grant Agreement No. 01.2.1-MITA-T-852-01-0106

Acute respiratory syndrome is the most common COVID-19 infection complication that might lead to death. One of the major causes of respiratory failure induced by the SARS-CoV-2 virus is extensive inflammatory response that damages cells of the respiratory system and impairs their function. To date, no effective therapeutic strategies have been developed to prevent COVID-19-induced acute respiratory distress, and the development of such strategies is of paramount importance. The project seeks to respond to this global need by developing a new cellular exosome biotechnology preparation for the prevention and treatment of acute respiratory failure caused by COVID-19 infection.

Operational programme for the European Union Funds Investments in Lithuania
We use cookies on this site. By clicking on the "I accept" button, or continue browsing you will confirm you acceptance. You can cancel your acceptance at any time by changing your browser settings and deleting saved cookies. Read Privacy Policy to learn more about our privacy and cookie policy.